Overview

Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
0
Participant gender:
All
Summary
Idiopathic Perifoveal telangiectasia is a poorly understood disorder that involves the growth of blood vessels around the center of the macula(perifoveal region). These blood vessels may extrend beneath the retina to produce an area of sub-retinal neosvascularization(growth of abnormal blood vessels under the retina which "leak" fluid, causing reduction in vision. Limited forms of treatment are available in managing the neovascularization and its consequences. Anecortave Acetate injection is considered as an attempt to control the growth of the abnormal blood vessels.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Manhattan Eye, Ear & Throat Hospital
Collaborator:
Alcon Research
Treatments:
Anecortave
Criteria
Inclusion Criteria:

1. Clinical diagnosis of patients with Idiopathic Perifoveal Telangiectasia(IPT).

2. Patients must be 18 years of age or older to receive treatment.

3. Visual acuity of 20/30 to 20/320 Study Eye on the ETDRS visual acuity chart.

4. Visual acuity of 20/800 or better Fellow Eye on the ETDRS visual acuity chart .

Exclusion Criteria:

1. Patient with significantly compromised visual acuity in the study eye due to
concomitant ocular conditions.

2. Patients who have undergone intraocular surgery within last 2 months.

3. Patient participating in any other investigational drug study.

3.Use of an investigational drug or treatment related or unrelated to their condition
within 30 days prior to receipt of study medication.

4.Inability to obtain photographs to document CNV (including difficulty with venous
access).

5.Patient with significant liver disease or uremia. 6.Patient with known adverse reaction
to fluorescein and indocyanine green or iodine.

7.Patient has a history of any medical condition which would preclude scheduled visits or
completion of study.

8.Patient has had insertion of scleral buckle in the study eye. 9.Patient has received
radiation treatment 10.Patient is on anticoagulant therapy with the exception of aspirin
11.Patient is pregnant or nursing.